查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2030 年荷爾蒙避孕藥市場預測：按產品類型、荷爾蒙、年齡層、性別、最終用戶和地區進行的全球分析
市場調查報告書
商品編碼
1383396

2030 年荷爾蒙避孕藥市場預測：按產品類型、荷爾蒙、年齡層、性別、最終用戶和地區進行的全球分析

Hormonal Contraceptives Market Forecasts to 2030 - Global Analysis By Product Type, Hormone, Age Group, Gender, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球荷爾蒙避孕藥市場規模為 183 億美元，預計到 2030 年將達到 282 億美元，預測期內年複合成長率為 6.3%。

作用於內分泌系統的避孕方法稱為荷爾蒙避孕藥。這些技術使用女性通常產生的荷爾蒙（例如黃體酮和雌激素）來防止排卵和懷孕。荷爾蒙避孕會改變子宮並降低懷孕的機會。荷爾蒙避孕藥有型態，包括皮膚貼片、藥丸、注射、手臂植入和子宮內避孕器。這些荷爾蒙避孕方法對於預防懷孕是可靠且安全的。超過 99% 的意外懷孕可以透過荷爾蒙避孕來避免。

根據世界衛生組織 (WHO) 的數據，現代避孕藥具普及率從 1990 年的 54% 上升到 2015 年的 57.4%。

世界人口成長

世界人口持續成長，這種人口趨勢導致對有效避孕方法的需求增加。荷爾蒙避孕藥因其可逆性、方便性以及幫助人們控制家庭規模和延遲或間隔懷孕的有效性而受到歡迎。隨著個人努力實現其理想的家庭規模並改善其經濟狀況，獲得有效的避孕方法變得至關重要。這些因素正在推動市場需求。

相關副作用

潛在的缺點包括鵝口瘡（陰道酵母菌感染疾病），以及頭痛、噁心和乳房疼痛等副作用。除了在月經期間感到沮喪和出血外，荷爾蒙還會降低女性的性慾。此外，形成血栓（血栓症）的可能性很小。吸菸、極度超重和有血管疾病家族病史的女性比 40 歲以上的女性有更高的風險。因此，這些缺點可能會阻礙市場擴張。

創新

藥物研究和開發的進步導致了新型和增強型荷爾蒙避孕藥的推出。其中包括低劑量製劑、長效可逆避孕藥 (LARC)，包括荷爾蒙子宮內避孕器和植入式植入，以及經皮經皮吸收貼片尖端給藥方法。技術創新增加了消費者的選擇並促進了市場的擴張。

法規政策及法規

市場可能會受到限制荷爾蒙避孕藥供應和使用的法律法規的顯著影響。在許多國家，嚴格的法規以及文化和宗教信仰限制或阻止荷爾蒙避孕藥的使用。然而，這些限制可能會阻礙市場擴張，並限制需求者獲得荷爾蒙避孕藥。

COVID-19 的影響

由於疫情期間計劃生育率下降以及避免意外懷孕的需要，COVID-19 對荷爾蒙避孕藥市場總體產生了一定程度的負面影響。這些避孕藥具主要用於計劃生育。診所關閉、預約取消和醫護人員短缺可能會限制避孕藥具的取得，尤其是荷爾蒙避孕藥。這些准入限制可能會減少荷爾蒙避孕藥的市場或增加低效避孕藥的使用。

口服避孕藥市場預計將在預測期內成為最大的市場

口服避孕藥市場估計佔最大佔有率。 OCP 已問世數十年，是最受歡迎的荷爾蒙避孕藥之一。口服避孕藥是尋求可靠避孕方法的人們的普遍選擇，因為如果正確和持續使用，它們相當有效。此藥的作用是抑制排卵、使子宮頸黏液變稠、削弱子宮內膜。每天服用口服避孕藥。在大多數配方中，您服用的藥丸有效期為 21 天，然後服用一週的無荷爾蒙藥丸或安慰劑。

預計醫院領域在預測期內的年複合成長率最高。

預計醫院部門在預測期內將出現良好的成長。促進該行業成長的關鍵因素是對這些荷爾蒙避孕藥的需求不斷成長而未得到滿足、新興經濟體中女性對不可逆避孕的偏好以及艾爾建和拜耳公司等公司的創新宮內避孕。其中包括設備的引進和多專科醫院的發展。此外，改善醫院藥局的投資正在增加，特別是在開發中國家。

佔比最高的地區

由於荷爾蒙避孕的高普及、該地區行業參與企業的強大影響力以及良好的醫療基礎設施等因素，北美在預測期內獲得了最大的市場佔有率。在北美，荷爾蒙避孕組織非常完善。該地區受益於避孕方法的高接受度和知識，以及透過藥房和保健醫生合理、方便地獲得荷爾蒙避孕藥。北美市場上有多種避孕方法，包括口錠劑、貼片、注射和子宮內避孕器 (IUD)。

複合年複合成長率最高的地區：

預計歐洲在預測期內將出現盈利成長。歐洲各地激素避孕藥的銷售活躍且多樣化。歐洲國家在避孕方面有不同的文化和法律實踐，導致產品可得性、處方要求和使用模式各不相同。許多生產和銷售荷爾蒙避孕藥的大型製藥企業也位於該地區。在歐洲國家，通常有多種避孕方法，包括口錠劑、貼片、環和植入。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計/預測/年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球荷爾蒙避孕藥市場：依產品類型

  • 介紹
  • 注射避孕藥
  • 口服避孕藥
  • 避孕環
  • 事後緊急避孕藥
  • 經皮吸收貼片
  • 複方口服避孕藥
  • 植入式避孕藥
  • 在子宮內

第6章 全球荷爾蒙避孕藥市場：依荷爾蒙分類

  • 介紹
  • 雌激素
  • 雄激素
  • 促性腺激素
  • 黃體素
  • 抗雄激素
  • 其他荷爾蒙

第7章 全球荷爾蒙避孕藥市場：依年齡層

  • 介紹
  • 15-24歲
  • 25-34歲
  • 35-44歲
  • 44歲以上

第8章 全球荷爾蒙避孕藥市場：性別

  • 介紹
  • 女士
  • 男性

第9章 全球荷爾蒙避孕藥市場：依最終用戶分類

  • 介紹
  • 家
  • 醫院
  • 診所
  • 零售藥房
  • 其他最終用戶

第10章 全球荷爾蒙避孕藥市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第11章進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章公司簡介

  • Bayer Healthcare Pharmaceuticals
  • Amgen
  • Cipla Limited
  • Novartis AG
  • Glenmark Pharmaceuticals
  • Pfizer, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Piramal Healthcare Limited
  • Teva Pharmaceutical Industries
  • Abbvie Inc.
  • Organon group of companies.
  • Agile Therapeutics
  • Janssen Pharmaceutical, Inc.
  • Pregna International Limited
  • Pantarhei Bioscience
  • Mayne Pharma Group Limited
Product Code: SMRC24246

According to Stratistics MRC, the Global Hormonal Contraceptives Market is accounted for $18.3 billion in 2023 and is expected to reach $28.2 billion by 2030 growing at a CAGR of 6.3% during the forecast period. Birth control treatments that work on the endocrine system are called hormonal contraceptives. These techniques involve using hormones that women typically make, including progesterone and estrogen to stop ovulation and pregnancy. Hormonal contraception alters the uterus, decreasing the possibility of pregnancy. Hormonal contraceptives come in several forms, including skin-attached patches, pills, injections, arm implants, and intrauterine devices. These hormonal contraceptive methods are trustworthy and safe for preventing pregnancy. Over 99% of unwanted pregnancies are avoided when hormonal contraceptives are used.

According to the World Health Organization, modern contraception rose from 54% in 1990 to 57.4% in 2015 globally.

Market Dynamics:

Driver:

Rising global population

The world's population continues to grow, and this demographic trend has contributed to the increasing demand for effective birth control methods. Hormonal contraceptives have gained popularity due to their reversible nature, ease, and effectiveness in helping people control the size of their families and postpone or space out pregnancies. As individuals strive to achieve their desired family size and improve their socioeconomic conditions, access to effective contraception becomes crucial. These factors propel market demand.

Restraint:

Associated side effects

Potential drawbacks include thrush, or vaginal yeast infections, along with side effects like headaches, nausea, and sore breasts. In addition to causing mood swings and spotting in between periods, the hormones may lessen women's desire for sex. Additionally, there is a slight chance that blood clots (thrombosis) will form. Women who smoke, are extremely overweight, or have a family history of vascular disease are more likely to be at risk than women over 40. Therefore, these related drawbacks might hinder market expansion.

Opportunity:

Technological innovations

New and enhanced hormonal contraceptive methods have been made available as a result of advancements in pharmaceutical research and development. Low-dose formulations, long-acting reversible contraceptives (LARCs), including hormonal IUDs and contraceptive implants, and cutting-edge delivery methods like Trans dermal patches are some of them. Technological innovations have increased consumer choice and promoted market expansion.

Threat:

Regulatory policies and restrictions

The market may be severely impacted by laws and regulations limiting the supply and use of hormonal contraceptives. Hormonal contraception use is restricted or hindered in many countries due to strict rules or cultural and religious beliefs. However, these limitations may impede the expansion of the market and restrict the availability of hormonal contraceptives to those who require them.

COVID-19 Impact

Due to the drop in family planning and the necessity to avoid unwanted pregnancies during the pandemic, COVID-19 has had a little negative overall influence on the market for hormonal contraceptives. These contraceptives are mostly used in family planning. Clinic closures, appointment cancellations, and a shortage of healthcare practitioners may have restricted access to contraception, particularly hormonal contraceptives. This restriction on access might have led to a decline in the market for hormonal contraceptives or an increase in the use of less potent forms of birth control.

The oral contraceptive pills segment is expected to be the largest during the forecast period

The oral contraceptive pills segment is estimated to hold the largest share. OCPs have been available for a number of decades and are among the most popular types of hormonal contraceptives. Oral contraceptive pills are a popular option for people looking for dependable contraception because they are quite effective when used appropriately and consistently. They function by inhibiting ovulation, thickening cervical mucus, and weakening the uterine lining, all of which block sperm from getting to the egg. Oral contraceptive pills are taken daily; most formulations require 21 days of active pills, followed by a week of hormone-free or placebo pills.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to have lucrative growth during the forecast period. The main factors contributing to segmental growth are the expanding unmet need for these hormonal forms of contraception, women's preference for irreversible contraception in emerging economies, the introduction of innovative intrauterine devices by corporations like Allergen and Bayer AG, and the development of multispecialty hospitals. Furthermore, due to the increasing investment in hospital pharmacy improvement, particularly in developing nations.

Region with largest share:

North America commanded the largest market share during the extrapolated period due to factors like the high rate of hormonal contraception uptake, the strong presence of industry players in the area, and superior healthcare infrastructure. Hormonal contraceptives have a well-established organization in North America. The region benefits from a high level of acceptance and knowledge of contraceptive methods and reasonably simple access to hormonal contraceptives via pharmacies and healthcare practitioners. A variety of contraceptive methods, such as oral tablets, patches, injections, and intrauterine devices (IUDs), are available in the North American market.

Region with highest CAGR:

Europe is expected to witness profitable growth over the projection period. Hormonal contraception sales are thriving and varied across Europe. Different European nations have different cultural and legal conventions around contraception, which causes variations in the availability of the product, prescription requirements, and patterns of use. Major pharmaceutical businesses that produce and market hormonal contraceptives are also heavily represented in the region. A variety of contraceptive techniques, such as oral tablets, patches, rings, and implants, are usually available in European countries.

Key players in the market

Some of the key players in the Hormonal Contraceptives Market include: Bayer Healthcare Pharmaceuticals, Amgen, Cipla Limited, Novartis AG, Glenmark Pharmaceuticals, Pfizer, Inc., Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Piramal Healthcare Limited, Teva Pharmaceutical Industries, Abbvie Inc., Organon group of companies, Agile Therapeutics, Janssen Pharmaceutical, Inc., Pregna International Limited, Pantarhei Bioscience and Mayne Pharma Group Limited.

Key Developments:

In May 2021, Pantarhei Bioscience made an announcement that the company got the approval for new oral contraceptive Estelle from the European Commission. With the approval of Estelle, contraceptive can be marketed in all the European states.

In April 2021, Mayne Pharma Group Limited and Mithra Pharmaceuticals announced the approval by U.S Food and Drug Administration (FDA) for oral contraceptive NEXTSTELLIS. It is the only contraceptive pill containing estetrol, which is produced from a plant source.

Product Types Covered:

  • Injectable Birth Control
  • Oral Contraceptive Pills
  • Vaginal Rings
  • Emergency Contraceptive Pills
  • Transdermal Patches
  • Combined Oral Contraceptives
  • Implanted Contraceptives
  • Intrauterine

Hormones Covered:

  • Estrogens
  • Androgens
  • Gonadotropins
  • Progestogens
  • Antiandrogens
  • Other Hormones

Age Groups Covered:

  • 15 To 24 Years
  • 25 To 34 Years
  • 35 To 44 Years
  • Above 44 Years

Genders Covered:

  • Female
  • Male

End Users Covered:

  • Household
  • Hospitals
  • Clinics
  • Retail Pharmacies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hormonal Contraceptives Market, By Product Type

  • 5.1 Introduction
  • 5.2 Injectable Birth Control
  • 5.3 Oral Contraceptive Pills
  • 5.4 Vaginal Rings
  • 5.5 Emergency Contraceptive Pills
  • 5.6 Transdermal Patches
  • 5.7 Combined Oral Contraceptives
  • 5.8 Implanted Contraceptives
  • 5.9 Intrauterine

6 Global Hormonal Contraceptives Market, By Hormone

  • 6.1 Introduction
  • 6.2 Estrogens
  • 6.3 Androgens
  • 6.4 Gonadotropins
  • 6.5 Progestogens
  • 6.6 Antiandrogens
  • 6.7 Other Hormones

7 Global Hormonal Contraceptives Market, By Age Group

  • 7.1 Introduction
  • 7.2 15 To 24 Years
  • 7.3 25 To 34 Years
  • 7.4 35 To 44 Years
  • 7.5 Above 44 Years

8 Global Hormonal Contraceptives Market, By Gender

  • 8.1 Introduction
  • 8.2 Female
  • 8.3 Male

9 Global Hormonal Contraceptives Market, By End User

  • 9.1 Introduction
  • 9.2 Household
  • 9.3 Hospitals
  • 9.4 Clinics
  • 9.5 Retail Pharmacies
  • 9.6 Other End Users

10 Global Hormonal Contraceptives Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Bayer Healthcare Pharmaceuticals
  • 12.2 Amgen
  • 12.3 Cipla Limited
  • 12.4 Novartis AG
  • 12.5 Glenmark Pharmaceuticals
  • 12.6 Pfizer, Inc.
  • 12.7 Lupin Pharmaceuticals, Inc.
  • 12.8 Sun Pharmaceutical Industries Ltd.
  • 12.9 Piramal Healthcare Limited
  • 12.10 Teva Pharmaceutical Industries
  • 12.11 Abbvie Inc.
  • 12.12 Organon group of companies.
  • 12.13 Agile Therapeutics
  • 12.14 Janssen Pharmaceutical, Inc.
  • 12.15 Pregna International Limited
  • 12.16 Pantarhei Bioscience
  • 12.17 Mayne Pharma Group Limited

List of Tables

  • Table 1 Global Hormonal Contraceptives Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Hormonal Contraceptives Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Hormonal Contraceptives Market Outlook, By Injectable Birth Control (2021-2030) ($MN)
  • Table 4 Global Hormonal Contraceptives Market Outlook, By Oral Contraceptive Pills (2021-2030) ($MN)
  • Table 5 Global Hormonal Contraceptives Market Outlook, By Vaginal Rings (2021-2030) ($MN)
  • Table 6 Global Hormonal Contraceptives Market Outlook, By Emergency Contraceptive Pills (2021-2030) ($MN)
  • Table 7 Global Hormonal Contraceptives Market Outlook, By Transdermal Patches (2021-2030) ($MN)
  • Table 8 Global Hormonal Contraceptives Market Outlook, By Combined Oral Contraceptives (2021-2030) ($MN)
  • Table 9 Global Hormonal Contraceptives Market Outlook, By Implanted Contraceptives (2021-2030) ($MN)
  • Table 10 Global Hormonal Contraceptives Market Outlook, By Intrauterine (2021-2030) ($MN)
  • Table 11 Global Hormonal Contraceptives Market Outlook, By Hormone (2021-2030) ($MN)
  • Table 12 Global Hormonal Contraceptives Market Outlook, By Estrogens (2021-2030) ($MN)
  • Table 13 Global Hormonal Contraceptives Market Outlook, By Androgens (2021-2030) ($MN)
  • Table 14 Global Hormonal Contraceptives Market Outlook, By Gonadotropins (2021-2030) ($MN)
  • Table 15 Global Hormonal Contraceptives Market Outlook, By Progestogens (2021-2030) ($MN)
  • Table 16 Global Hormonal Contraceptives Market Outlook, By Antiandrogens (2021-2030) ($MN)
  • Table 17 Global Hormonal Contraceptives Market Outlook, By Other Hormones (2021-2030) ($MN)
  • Table 18 Global Hormonal Contraceptives Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 19 Global Hormonal Contraceptives Market Outlook, By 15 To 24 Years (2021-2030) ($MN)
  • Table 20 Global Hormonal Contraceptives Market Outlook, By 25 To 34 Years (2021-2030) ($MN)
  • Table 21 Global Hormonal Contraceptives Market Outlook, By 35 To 44 Years (2021-2030) ($MN)
  • Table 22 Global Hormonal Contraceptives Market Outlook, By Above 44 Years (2021-2030) ($MN)
  • Table 23 Global Hormonal Contraceptives Market Outlook, By Gender (2021-2030) ($MN)
  • Table 24 Global Hormonal Contraceptives Market Outlook, By Female (2021-2030) ($MN)
  • Table 25 Global Hormonal Contraceptives Market Outlook, By Male (2021-2030) ($MN)
  • Table 26 Global Hormonal Contraceptives Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Hormonal Contraceptives Market Outlook, By Household (2021-2030) ($MN)
  • Table 28 Global Hormonal Contraceptives Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 29 Global Hormonal Contraceptives Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 30 Global Hormonal Contraceptives Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 31 Global Hormonal Contraceptives Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.